HOTH earnings analysis
What we found in HOTH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Hoth Therapeutics, Inc. exhibited a significant reduction in its net loss for Q1 2026 compared to Q1 2025, decreasing from a loss of $3,476,000 (-$0.27 EPS) to $2,692,000 (-$0.17 EPS). Despite maintaining the same segment focus, the company has not yet generated revenue and continues to rely on equity and debt financing for operations. With a cash position of approximately $4,047,000, HOTH faces liquidity challenges going forward without additional funding.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduced Net Loss
- Net loss narrowed to $2,692,000 in Q1 2026 from $3,476,000 in Q1 2025, reflecting a tighter expense management.
- Decreased G&A Expenses
- General and administrative expenses dropped 25.6%, from $1,517,000 in Q1 2025 to $1,129,000 in Q1 2026.
- Increased R&D Efficiency
- R&D costs decreased to $1,519,000 in Q1 2026 from $1,959,000 in Q1 2025 as the company streamlined its focus on key projects.
- Cash Position Improvement
- As of March 31, 2026, cash and cash equivalents stood at $4,047,000, ensuring operational liquidity.
- Warrants Issued
- Net proceeds of approximately $2,000,000 were raised from the sale of 2,857,144 shares of common stock at $0.70.
- Stable Working Capital
- Working capital is approximately $3,425,000, with the ability to support operations through the current quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Losses
- The company reported net losses of $2,692,000 in Q1 2026, reflecting challenges in achieving operational profitability.
- Liquidity Concerns
- Firm projects a risk of failing to fund operations for at least 12 months without additional financing due to current cash availability.
- Dependence on Financing
- Significant future funding will be necessary for continued clinical and pre-clinical activities without any current revenue generation.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.17
What they said about what is next.
Management did not provide explicit numeric guidance but indicated challenges in securing funding.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HOTH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever